Search

The new EU clinical trials map is online

A new clinical trial map was launched by EMA as part of the Clinical Trials Information System (CTIS) on March 3.

Read more

EHA-SWG Scientific Meeting "Patient-centered Geriatric Hematology"

EHA & the EHA Scientific Working Group on Hematology and Aging are happy to announce their recent collaboration in organizing a virtual meeting program providing delegates with the latest insights in the field of geriatric hematology, presented by leading hematologists.

Read more

GoCART Coalition - Call for research proposals within Work Package 6: Scientific Excellence

Dear GoCART community, 

With more than 1500 CAR-T infusions registered in the EBMT registry, EHA and EBMT are proud to announce a series of scientific calls within Work Package 6: Scientific Excellence of the GoCART coalition.

Read more

European registry on inherited platelet disorders project, February 2025

A project update from Prof Paolo Gresele. We successfully completed the CRF harmonization phase and are now in the process of finalizing and launching the registry platform.

Read more

Young researchers to benefit from EHA training and mentoring

Participation in EHA-CRTH will allow these researchers to fine-tune the skills and knowledge required to successfully design, run and complete clinical trials.

Read more

Nurses abstract submission

Abstract and Case Report submission for nurses is now closed. Nurses abstract submissionDon’t miss out on a great opportunity to submit an abstract for the 6th EHA-EBMT European CAR T-cell Meeting 2024.

Read more

Celebrating the International Day of Women & Girls in Science

On this International Day of Women & Girls in Science, we take a moment to honor, appreciate and thank, all the women scientists at the forefront of the fight against COVID-19.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more